1. FIFTEEN-YEAR RADIOTHERAPY OUTCOMES OF THE RANDOMIZED PORTEC-1 TRIAL FOR ENDOMETRIAL CARCINOMA
- Author
-
Creutzberg, C.L., Nout, R.A., Lybeert, M.L.M., Warlam-Rodenhuis, C.C., Jobsen, J.J., Mens, J.W.M., Lutgens, L.C.H.W., Pras, E., Poll-Franse, L.V. van de, Putten, W.L.J. van, PORTEC Study Grp, Medical and Clinical Psychology, Radiotherapie, and RS: GROW - School for Oncology and Reproduction
- Subjects
Oncology ,Cancer Research ,INTERMEDIATE-RISK ,medicine.medical_treatment ,ComputingMilieux_LEGALASPECTSOFCOMPUTING ,GYNECOLOGIC-ONCOLOGY-GROUP ,law.invention ,ADJUVANT CHEMOTHERAPY ,POSTOPERATIVE RADIOTHERAPY ,Quality of life ,Randomized controlled trial ,QUALITY-OF-LIFE ,law ,Stage (cooking) ,Aged, 80 and over ,Radiation ,Neoplasms, Second Primary ,PHASE-III TRIAL ,Middle Aged ,Prognosis ,LYMPHVASCULAR SPACE INVOLVEMENT ,Radiation therapy ,Treatment Outcome ,Radiology Nuclear Medicine and imaging ,Female ,Randomized trial ,PELVIC RADIATION-THERAPY ,Adult ,Risk ,medicine.medical_specialty ,Vaginal Neoplasms ,Breast Neoplasms ,Endometrial carcinoma ,Prognostic factors ,Disease-Free Survival ,Stage ib ,Internal medicine ,Carcinoma ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,External beam radiotherapy ,Aged ,Analysis of Variance ,Intention-to-treat analysis ,business.industry ,medicine.disease ,Long-term outcome ,Endometrial Neoplasms ,Surgery ,CANCER MRC ASTEC ,EXTERNAL-BEAM RADIOTHERAPY ,Neoplasm Grading ,Neoplasm Recurrence, Local ,business - Abstract
Purpose: To evaluate the very long-term results of the randomized Post Operative Radiation Therapy in Endometrial Carcinoma (PORTEC)-1 trial for patients with Stage I endometrial carcinoma (EC), focusing on the role of prognostic factors for treatment selection and the long-term risk of second cancers.Patients and Methods: The PORTEC trial (1990-1997) included 714 patients with Stage IC Grade 1-2 or Stage IB Grade 2-3 EC. After surgery, patients were randomly allocated to external-beam pelvic radiotherapy (EBRT) or no additional treatment (NAT). Analysis was by intention to treat.Results: 426 patients were alive at the date of analysis. The median follow-up time was 13.3 years. The 15-year actuarial locoregional recurrence (LRR) rates were 6% for EBRT vs. 15.5% for NAT (p 60 (HR 3.9, p = 0.002 for LRR and 2.7, p = 0.01 for EC death) and myometrial invasion > 50% (HR 1.9, p = 0.03 and HR 1.9, p = 0.02).Conclusions: The 15-year outcomes of PORTEC-1 confirm the relevance of HIR criteria for treatment selection, and a trend for long-term risk of second cancers. EBRT should be avoided in patients with low-and intermediate-risk EC. (C) 2011 Elsevier Inc.
- Published
- 2011